2069 completed, 631 terminated, 621 recruiting, 488 unknown. 1897 Phase 2, 1473 Phase 1, 506 Not applicable, 268 Phase 3, 84 Early Phase 1.
Follow Neuroendocrine Tumors: new trials by email Literature Review of Neuroendocrine Tumors trials Research Report on Neuroendocrine Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection Biospecimen Collection, FDG-Positron Emission Tomography and Computed Tomography Scan, Ga-68 PET/CT Scan - Thyroid Gland Medullary Carcinoma | Not applicable | Not yet recruiting | Jonsson Comprehensive Cancer Center | 100 | 2027-09-02 | 2026-10-19 |
| Combination Immunotherapy Targeting Melanoma Antigen-specific CAR T, CTL and DCvac to treat melanoma. - Melanoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-10-30 |
| Trial of Temozolomide in BAP1 Mutated Patients With Advanced or Metastatic Cutaneous Melanoma Temozolomide (TMZ) - Cutaneous Melanoma | Phase 2 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 28 | 2027-06-01 | 2026-09-08 |
| A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information Biospecimen Collection, Chest Radiography, Computed Tomography - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | Children's Oncology Group | 51 | 2027-05-15 | 2026-09-24 |
| Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma | Phase 2 | Not yet recruiting | Northwestern University | 56 | 2027-05-05 | 2026-10-07 |
| Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma RAPA-201 Rapamycin Resistant T Cells, Chemotherapy Prior to RAPA-201 Therapy - Malignant Melanoma With Metastasis, Malignant Melanoma | Phase 2 | Not yet recruiting | Rapa Therapeutics LLC | 65 | 2027-03-01 | 2026-03-19 |
| STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) Ivonescimab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2027-02-07 | 2026-09-18 |
| Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2 - Uveal Melanoma, Metastatic Cutaneous Melanoma | Phase 1 | Not yet recruiting | Vastra Gotaland Region | 6 | 2027-01-31 | 2026-09-09 |
| Zanzalintinib in Unresectable and Progressive MPGGs Zanzalintinib - Pheochromocytoma, Paraganglioma | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 14 | 2027-01-09 | 2026-07-20 |
| Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults Mirdametinib - LGCMN, Large and Giant Congenital Melanocytic Nevi | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 15 | 2027-01-04 | 2026-10-29 |
| Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma Autologous Tumor Infiltrating Lymphocytes (TIL), Melphalan, Interleukin-2 - Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma | Phase 1 | Not yet recruiting | Vastra Gotaland Region | 18 | 2027-01-01 | 2026-09-09 |
| Role of ChatGPT in Vestibular Schwannoma Management Use of chatGPT for 1 week - Vestibular Schwannoma | Not applicable | Withdrawn | University of Southern California | 2027-01-01 | 2026-01-13 | |
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | Not applicable | Not yet recruiting | Natera, Inc. | 920 | 2027-01-01 | 2026-10-27 |
| Study of ACC-1898 in Adult Participants With Advanced Solid Tumors ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1 | Not yet recruiting | AccSalus Biosciences, Inc. | 40 | 2027-01-01 | 2026-10-28 |
| Prospective, Multi-Center Observational Registry of Melanoma CP-GEP and Clinical Outcomes Melanoma (Skin Cancer), Gene Expression Profiling | Not yet recruiting | SkylineDx | 2000 | 2027-01-01 | 2026-11-13 | |
| Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study ICI Therapy - Gastrointestinal Neoplasms, Genitourinary Cancer | Early Phase 1 | Not yet recruiting | Indiana University | 80 | 2027-01-01 | 2026-11-18 |
| Neoadjuvant RP2 + Nivolumab in Patients With Melanoma RP2 (vusolimogene oderparepvec), Nivolumab, Definitive Surgical Resection - MelanomaCutaneous Melanoma Resectable, Melanoma | Phase 2 | Not yet recruiting | Yana Najjar | 34 | 2026-12-31 | 2026-10-07 |
| Trial Comparing CPDMA Versus Standard Breadloafing in WLE Specimens of Stage 1-II Cutaneous Melanoma Wide Local Excision - Cutaneous Melanoma, Stage II, Cutaneous Melanoma | Not applicable | Not yet recruiting | University of Nebraska | 282 | 2026-12-24 | 2026-10-09 |
| Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy Biospecimen Collection, Internet-Based Intervention, Medical Device Usage and Evaluation - Advanced Cutaneous Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 1 | Not yet recruiting | City of Hope Medical Center | 8 | 2026-12-23 | 2026-06-05 |
| Everolimus Post-Bland Hepatic Artery Embolization in Patients With Neuroendocrine Tumors (NETs) With Liver Metastasis Everolimus, Bland Hepatic Artery Embolization - Neuroendocrine Tumors, Liver Metastases | Phase 2 | Not yet recruiting | Lowell Anthony, MD | 12 | 2026-12-16 | 2026-11-18 |
Showing 20 of 4550. Sign in to see all of them.
Melanoma (3205) · Carcinoma, Non-Small-Cell Lung (451) · Neoplasms (399) · Neoplasm Metastasis (353) · Carcinoma, Renal Cell (325) · Breast Neoplasms (319) · Uveal Melanoma (280) · Colorectal Neoplasms (257) · Lung Neoplasms (246) · Skin Neoplasms (221) · Ovarian Neoplasms (209) · Sarcoma (202) · Pancreatic Neoplasms (201) · Squamous Cell Carcinoma of Head and Neck (178)
Neuroectodermal Tumors (4544) · Neoplasms by Histologic Type (4534) · Neoplasms, Germ Cell and Embryonal (4531) · Neoplasms, Nerve Tissue (4513) · Neoplasms (4151) · Neoplasms by Site (3836) · Nevi and Melanomas (3376) · Skin and Connective Tissue Diseases (3269) · Skin Diseases (3256) · Skin Neoplasms (3008) · Neoplasms, Glandular and Epithelial (1240) · Carcinoma (1068) · Adenocarcinoma (914) · Thoracic Neoplasms (679)
pembrolizumab (340) · Nivolumab (315) · Ipilimumab (282) · Cyclophosphamide (151) · aldesleukin (145) · Interleukin-2 (112) · Temozolomide (105) · trametinib (85) · Dacarbazine (83) · dabrafenib (77) · fludarabine (75) · Vemurafenib (71) · Bevacizumab (68) · Everolimus (67) · fludarabine phosphate (65)
National Cancer Institute (NCI) (288) · M.D. Anderson Cancer Center (135) · Bristol-Myers Squibb (90) · Memorial Sloan Kettering Cancer Center (86) · Novartis Pharmaceuticals (70) · H. Lee Moffitt Cancer Center and Research Institute (53) · Hoffmann-La Roche (48) · Mayo Clinic (47) · Pfizer (42) · Merck Sharp & Dohme LLC (39) · Dana-Farber Cancer Institute (37) · GlaxoSmithKline (28) · University Medical Center Groningen (28) · Massachusetts General Hospital (27) · University Health Network, Toronto (27)
United States (2612) · France (513) · Italy (382) · Spain (361) · Germany (359) · United Kingdom (350) · Australia (331) · Canada (317) · China (291) · Netherlands (246) · Belgium (199) · Switzerland (177) · Poland (148) · Israel (126) · South Korea (125)
Steven A Rosenberg, M.D. (30) · Steven A. Rosenberg, MD, PhD (27) · F. Stephen Hodi, MD (14) · Paul Chapman, MD (10)
PMID 36648215, PMID 25667295, PMID 24983357, PMID 39504507, PMID 22555974, PMID 22256804, PMID 25649350, PMID 26446943, PMID 31395089, PMID 31401903, PMID 32746839, PMID 37934000, PMID 23457002, PMID 23861247, PMID 24408395, PMID 24577748, PMID 27864013, PMID 30202085, PMID 30736858, PMID 32305010, PMID 32747469, PMID 33360855, PMID 34225229, PMID 34754076, PMID 36653848, PMID 39462179, PMID 40341199, PMID 40721981, PMID 41811823, PMID 17917842, PMID 19097774, PMID 19574236, PMID 19645909, PMID 20856802, PMID 21600759, PMID 21639810, PMID 22027076, PMID 23054107, PMID 23295794, PMID 23504141, PMID 23676418, PMID 24145345, PMID 24418949, PMID 24695685, PMID 25432172, PMID 25837513, PMID 26247776, PMID 26902923, PMID 28592387, PMID 28662232
2023 (45), 2019 (38), 2016 (30), 2018 (28), 2014 (20), 2015 (18), P30CA015083 (18), U10CA032102 (16), P30CA016672 (15), U10CA180820 (15), 2025 (13), 2009 (12), 2017 (12), P30CA015704 (12), P30CA072720 (12)